Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort

Autor: Sydney Pomenti, Cassandra Gandle, Hamzah Abu Sbeih, Meaghan Phipps, Alexandra Livanos, Averill Guo, Jonathan Yeh, Heather Burney, Hao Liu, Lara Dakhoul, Carla Kettler, Samer Gawrieh, Andrew deLemos, Andrew Scanga, Naga Chalasani, Ethan Miller, Julia Wattacheril

Publikováno v: Hepatology Communications, Vol 4, Iss 11, Pp 1708-1716 (2020)

Hepatocellular carcinoma (HCC) has a strong racial and ethnic association, with Hispanic patients having a higher incidence and mortality. However, there are limited data regarding clinical features and outcomes. This study includes Hispanic and non�

Externí odkaz: https://doaj.org/article/5f411221c27049c7a0f42c2832c86eff

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

Autor: Cynthia Levy, Deven Parmar, Andrew deLemos, Simona Rossi, Aasim Sheikh, Naga Chalasani, Nikolaos Pyrsopoulos, Edward Mena, David S. Goldberg, Stephen H. Caldwell, Farheen Shaikh, Ravi Ravinuthala, Raj Vuppalanchi, James D. Bainbridge

Publikováno v: Journal of Hepatology. 76:75-85

Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with dual agonistic properties (α/γ). Due to a strong mechanistic rationale, we aimed to test the safety and efficacy of saroglitazar in patients with primary biliary

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23fb0670d05197117ec96c6b68cf5c18
https://doi.org/10.1016/j.jhep.2021.08.025

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents

Autor: Naga Chalasani, Lauren Nephew, Milin Patel, Heather Burney, Karan Mathur, Hao Liu, Areej Mazhar, Lara Dakhoul, Samer Gawrieh, Andrew deLemos

Publikováno v: Clinical and Translational Gastroenterology

Introduction The impact of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) on burden of cirrhotic and noncirrhotic hepatocellular carcinoma (HCC) has not been examined. We assessed recent trends in liver disease etiologies of HCC and prop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0926e968d8781a6f02e164786f99b16c
https://pubmed.ncbi.nlm.nih.gov/34730559

Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States

Autor: Julia Wattacheril, Ethan Miller, Meaghan Phipps, Averill Guo, Alexandra E. Livanos, Jonathan Yeh, Sydney Pomenti, Samer Gawrieh, Hao Liu, Naga Chalasani, Heather Burney, Carla Kettler, Andrew Scanga, Lara Dakhoul, Andrew deLemos

Publikováno v: The American journal of gastroenterology. 115(9)

INTRODUCTION Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide, affecting men to women at a ratio of about 4:1. Risk factors, characteristics, and outcomes for HCC in women in the United States remain poorly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4327b785afe1190c28e69f075970f1e9
https://pubmed.ncbi.nlm.nih.gov/33657046

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

Autor: Fernando Membreno, Giuseppe Morelli, Ray Thomason, Kalyan Ram Bhamidimarri, Dawn Torres, Andrew Scanga, Danielle Brandman, Guy W. Neff, Mark McKenzie, Stephen H. Caldwell, Kathleen E. Corey, Nadeem Anwar, Kimberly A. Brown, James Strobel, Sammy Saab, Thomas Amankonah, Bal R. Bhandari, Souvik Sarkar, Don C. Rockey, Miguel Á. Rodríguez, Mazen Noureddin, Edward Mena, Nikolaos Pyrsopoulos, Ayman Koteish, Gary A. Abrams, Andrew DeLemos, Richard Frederick, Bhaktasharan Patel, David T. Hagerty, Amy Stratton, Kathryn J. Lucas, Ethan M. Weinberg, Zeid Kayali, Anita Kohli, Marina Roytman, Kris V. Kowdley, Nicole Wedick, Brett E. Fortune, Michael P. Curry, Sofia Jakab, Kiran Bambha, Satinder Gill, Stevan A. Gonzalez, Nikunj Shah, Warren N. Schmidt, Jean L. Chan, Charles S. Landis, Bradley Freilich, Catherine Frenette, Hugo E. Vargas, Mary E. Rinella, Mohammad S. Siddiqui, Andrew P. Keaveny, George Therapondos, Elizabeth C. Verna, Ray Kim, James M. Robinson, David I. Bernstein, Marwan Ghabril, Reem Ghalib, John M. Vierling, Manal F. Abdelmalek, Paul J. Thuluvath, Jen-Jung Pan, Ravi Ravendhran, Amanda Wieland, Eric Lawitz, Justin Reynolds, Victor Ankoma-Sey, Mitchell L. Shiffman, Nyingi Kemmer, William M. Lee, Viviana Figueroa-Diaz, Douglas A. Simonetto, Jonathan Huang, Aasim Sheikh, Parvez S. Mantry, Harvey Tatum, Lance Stein

Publikováno v: Journal of hepatology. 74(2)

Background & Aims Non-alcoholic steatohepatitis is a leading cause of end-stage liver disease. Hepatic steatosis and lipotoxicity cause chronic necroinflammation and direct hepatocellular injury resulting in cirrhosis, end-stage liver disease and hep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76272acaeb30d8a655a783c8511b9b83
https://pubmed.ncbi.nlm.nih.gov/33038432